Company intelligence / Profile preview

All Shapes

Seattle, Washington, United Statesabcteach.com ↗

Ownership: Private
Development stage: Other

Overview

Shape Therapeutics leverages artificial intelligence, synthetic biology, and advanced RNA technology to develop programmable medicines that can correct mutations or modulate gene expression at the RNA level. Their lead technology, RNAfix®, recruits endogenous ADAR enzymes to recode specific RNAs without altering DNA. The company has been recognized as an innovative leader in programmable medicine. Clinical results are not yet public; programs are likely preclinical or entering early clinical development.

Therapeutic areas: Rare Diseases
Modalities: RNA therapymRNA-based drugsSynthetic oligonucleotide
Industry: Biotech

Beyond the preview

Go deeper on All Shapes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on All Shapes.

Explore the full profile